References
- Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002; 23: 41–43
- Hiranita T, Nawata Y, Sakimura K, Anggadiredja K, Yamamoto T. Suppression of methamphetamine-seeking behavior by nicotinic agonists. Proc Natl Acad Sci USA 2006; 103: 8523–8527
- Maidment, I, Fox, C, Boustani, M. 2006. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev, DOI: 10.1002/14651858.CD004747.pub2.
- Misra LK, Kofoed L, Oesterheld JR, Richards GA. Olanzapine treatment of methamphetamine psychosis. J Clin Psychopharmacol 2000; 20: 393–394
- Moszczynska A, Fitzmaurice P, Ang L, Kalasinsky KS, Schmunk GA, Peretti FJ, et al. Why is parkinsonism not a feature of human methamphetamine users?. Brain 2004; 127: 363–370